FDA approves Sage's first-ever treatment for postpartum depression

The FDA has approved Cambridge biopharma Sage Therapeutics' first product, a drug that the company says will be the first product specifically designed to treat postpartum depression. Zulresso is Sage's (Nasdaq: SAGE) first product to reach the market and one of two treatments the company has developed to treat postpartum depression. Its second potential therapy, an oral medication known as SAGE 217, succeeded in a late-stage trial as a postpartum treatment and is also being ev aluated as a potential…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news